Sher Karki

6.6k total citations · 1 hit paper
38 papers, 4.4k citations indexed

About

Sher Karki is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cell Biology. According to data from OpenAlex, Sher Karki has authored 38 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 20 papers in Molecular Biology and 14 papers in Cell Biology. Recurrent topics in Sher Karki's work include Monoclonal and Polyclonal Antibodies Research (21 papers), Microtubule and mitosis dynamics (12 papers) and Cellular transport and secretion (10 papers). Sher Karki is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), Microtubule and mitosis dynamics (12 papers) and Cellular transport and secretion (10 papers). Sher Karki collaborates with scholars based in United States, Germany and Canada. Sher Karki's co-authors include Erika L.F. Holzbaur, Greg A. Lazar, John R. Desjarlais, Mariko Tokito, Clare M. Waterman, Hsing Chen, Elizabeth A Holleran, Wei Dang, Holly M. Horton and Gregory L. Moore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Sher Karki

38 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineered antibody Fc variants with enhanced effector function

2006 590 citations Greg A. Lazar, Wei Dang et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sher Karki United States	27	2.6k	1.7k	1.6k	1.0k	646	38	4.4k
Fedor Berditchevski United Kingdom	40	2.7k 1.0×	440 0.3×	1.8k 1.1×	1.1k 1.1×	729 1.1×	72	5.5k
Yuji Yamanashi Japan	43	3.5k 1.3×	784 0.5×	817 0.5×	2.3k 2.2×	1.2k 1.9×	94	7.1k
Brian A. Pollok United States	22	2.6k 1.0×	429 0.3×	459 0.3×	818 0.8×	617 1.0×	41	4.0k
Sylvie Marchetto France	34	1.9k 0.7×	362 0.2×	620 0.4×	962 0.9×	551 0.9×	62	3.8k
Ritu Dhand United Kingdom	21	4.8k 1.8×	296 0.2×	1.5k 0.9×	865 0.8×	1.0k 1.6×	26	6.1k
Nobuo Nomura Japan	31	3.4k 1.3×	578 0.3×	871 0.5×	368 0.4×	1.2k 1.8×	70	4.7k
Kouichi Tachibana Japan	32	2.2k 0.8×	330 0.2×	1.0k 0.6×	890 0.9×	400 0.6×	70	3.7k
Jürgen Wienands Germany	39	1.7k 0.6×	816 0.5×	304 0.2×	3.2k 3.1×	683 1.1×	100	5.0k
C. Jane McGlade Canada	37	4.0k 1.5×	260 0.2×	1.5k 0.9×	1.9k 1.8×	879 1.4×	78	6.1k
Nina Marie Pedersen Norway	38	2.7k 1.0×	250 0.1×	1.5k 0.9×	339 0.3×	882 1.4×	75	4.6k

Countries citing papers authored by Sher Karki

Since Specialization

Citations

This map shows the geographic impact of Sher Karki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sher Karki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sher Karki more than expected).

Fields of papers citing papers by Sher Karki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sher Karki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sher Karki. The network helps show where Sher Karki may publish in the future.

Co-authorship network of co-authors of Sher Karki

This figure shows the co-authorship network connecting the top 25 collaborators of Sher Karki. A scholar is included among the top collaborators of Sher Karki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sher Karki. Sher Karki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nisthal, Alex, Sung‐Hyung Lee, Christine Bonzon, et al.. (2022). 1372 XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP. Regular and Young Investigator Award Abstracts. A1426–A1426. 3 indexed citations

Zhao, Hui, Sathish Kumar Ganesan, Karen Morrison, et al.. (2017). Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia. Molecular Cancer Therapeutics. 16(9). 1877–1886. 47 indexed citations

Karki, Sher, Héctor Aviña, Ahmed Sawas, et al.. (2017). Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients. Cancer Research. 77(13_Supplement). 2709–2709. 1 indexed citations

Manocha, Gunjan D., Angela M. Floden, Joshua A. Kulas, et al.. (2016). APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 36(32). 8471–8486. 45 indexed citations

Moore, Gregory L., Erik Pong, Duc-Hanh T. Nguyen, et al.. (2011). A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs. 3(6). 546–557. 89 indexed citations

Zalevsky, Jonathan, Aaron K. Chamberlain, Holly M. Horton, et al.. (2010). Enhanced antibody half-life improves in vivo activity. Nature Biotechnology. 28(2). 157–159. 449 indexed citations

Moore, Gregory L., Hsing Chen, Sher Karki, & Greg A. Lazar. (2010). Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs. 2(2). 181–189. 193 indexed citations

Horton, Holly M., Matthew J. Bernett, Erik Pong, et al.. (2008). Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia. Cancer Research. 68(19). 8049–8057. 187 indexed citations

Richards, John O., Sher Karki, Greg A. Lazar, et al.. (2008). Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Molecular Cancer Therapeutics. 7(8). 2517–2527. 235 indexed citations

10.

Chu, Seung Y., Igor Voštiar, Sher Karki, et al.. (2008). Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology. 45(15). 3926–3933. 119 indexed citations

11.

Lazar, Greg A., Wei Dang, Sher Karki, et al.. (2006). Engineered antibody Fc variants with enhanced effector function. Proceedings of the National Academy of Sciences. 103(11). 4005–4010. 590 indexed citations breakdown →

12.

Lazar, Greg A., John R. Desjarlais, Jonathan Jacinto, Sher Karki, & Philip W. Hammond. (2006). A molecular immunology approach to antibody humanization and functional optimization. Molecular Immunology. 44(8). 1986–1998. 78 indexed citations

13.

Karki, Sher, et al.. (2002). PLAC-24 Is a Cytoplasmic Dynein-Binding Protein That Is Recruited to Sites of Cell-Cell Contact. Molecular Biology of the Cell. 13(5). 1722–1734. 19 indexed citations

14.

Ligon, Lee A., Sher Karki, Mariko Tokito, & Erika L.F. Holzbaur. (2001). Dynein binds to β-catenin and may tether microtubules at adherens junctions. Nature Cell Biology. 3(10). 913–917. 230 indexed citations

15.

Karki, Sher, Mariko Tokito, & Erika L.F. Holzbaur. (2000). A Dynactin Subunit with a Highly Conserved Cysteine-rich Motif Interacts Directly with Arp1. Journal of Biological Chemistry. 275(7). 4834–4839. 32 indexed citations

16.

Karki, Sher & Erika L.F. Holzbaur. (1999). Cytoplasmic dynein and dynactin in cell division and intracellular transport. Current Opinion in Cell Biology. 11(1). 45–53. 385 indexed citations

17.

Holleran, Elizabeth A, Sher Karki, & Erika L.F. Holzbaur. (1998). The Role of the Dynactin Complex in Intracellular Motility. International review of cytology. 182. 69–109. 124 indexed citations

18.

Walter, Steffen, Sher Karki, Kevin T. Vaughan, et al.. (1997). The Involvement of the Intermediate Chain of Cytoplasmic Dynein in Binding the Motor Complex to Membranous Organelles ofXenopusOocytes. Molecular Biology of the Cell. 8(10). 2077–2088. 99 indexed citations

19.

Karki, Sher, et al.. (1997). Casein Kinase II Binds to and Phosphorylates Cytoplasmic Dynein. Journal of Biological Chemistry. 272(9). 5887–5891. 57 indexed citations

20.

Karki, Sher & Erika L.F. Holzbaur. (1995). Affinity Chromatography Demonstrates a Direct Binding between Cytoplasmic Dynein and the Dynactin Complex. Journal of Biological Chemistry. 270(48). 28806–28811. 285 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact